Revenue Generation Through Upfront Payments, Research Support Payments, Milestones and Royalties
First written in FY2023. 4 of 5 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「Research support payment revenue 35,000 Contract research revenue 1,400 Revenue from contracts with customers 36,400」
The company continues to monetize primarily through research support payments and contract research revenue under joint drug-discovery research agreements. During the interim accounting period, contract revenue comprised ¥35.0 million in research support payments and ¥1.4 million in contract research revenue. - FY2025RestatedAnnual report
「In our agreements with pharmaceutical companies, we seek to secure long-term, recurring business revenue from immediately after the conclusion of an agreement by stipulating not only upfront payments and research support payments, but also consideration in the form of milestones, royalties and other payments.」
The company continues its monetization model combining upfront payments, research support payments, research, development and sales milestones, and royalties. - FY2025-H1RestatedAnnual report
「In terms of revenue, we recorded business revenue of ¥43,420 thousand, down 62.6% year on year, from recurring research support payments received under joint drug-discovery research agreements and milestone revenue received on an occasional basis.」
The company continues to center its monetization model on research support payments under joint research agreements and occasional milestone revenue. - FY2024-H1RestatedAnnual report
「In terms of revenue, we recorded business revenue of ¥115,998 thousand from recurring research support payments received under joint drug-discovery research agreements and milestone revenue received on an occasional basis.」
The company continues to monetize its business primarily through research support payments and milestone revenue under joint drug-discovery research agreements. - FY2023First statedAnnual report
「In our agreements with pharmaceutical companies, we seek to secure long-term, recurring business revenue from immediately after the conclusion of an agreement by stipulating not only upfront payments and research support payments, but also consideration in the form of milestones, royalties and other payments.」
The core business model is a contract structure that generates revenue from the start of research and development through each stage of research, development and sales.